Under the terms of the deal, Purdue Pharma will become a public benefit company, with profits directed toward opioid addiction.

All 50 states, D.C., and four U.S. territories signed off on the multi-billion dollar settlement proposal with OxyContin maker Purdue Pharma in litigation over Purdue's alleged role in America's opioid addiction crisis.

The deal ends the Sackler family's ownership of the company and bans them from ever selling opioids in the U.S. again.